***Pharmaceutical Benefits Advisory Committee***

Telephone: (02) 6289 7099 Address all mail to:

Email: PBAC@health.gov.au PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELETION OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 1 July 2020**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the deletion of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Prasugrel | The sponsor has requested the deletion of Effient® due to a decision by the sponsor to discontinue the product on 1/7/2020.  It was noted that there are no other prasugrel products available, but there are other PBS listed platelet aggregation inhibitors for acute coronary syndrome.  At its 27 February 2020 teleconference, the Executive noted that there was not a significantly large usage, and that clopidogrel was the market leader. The Executive therefore considered that the deletion was unlikely to cause an unmet clinical need. |

Michelle Green

Acting Director

Committee Support Unit

Office of Health Technology Assessment

Technology Assessment and Access Division

16 June 2020